GoAI
Get started
Assembly Biosciences, Inc. logo

Assembly Biosciences, Inc.

ASMB

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$34.38

+$0.85 · +2.54%

Aug 21, 4:00 PM ET

ASMB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

78

Undervalued

Momentum

43

Neutral

Sentiment

70

Bullish

Risk resilience

40

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jason A. Okazaki
Listed since
Dec 17, 2010
Employees
73

Market position

Day range

Current $34.38

52-week range

Current $34.38

Open
$33.86
Previous close
$33.53
Volume
341.54K
1.67× average
Average volume
204.68K
Average daily volume
Market cap
681.32M USD
Beta
1.09
Market reference 1
50-day average
$26.9718
+27.47% above average
200-day average
$29.22
+17.66% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
325.46M USD
P/E (TTM)
62.51×
P/B (TTM)
2.12×
P/S (TTM)
9.1×
EV / EBITDA
-54.31×
Earnings yield
-1.61%
Free cash flow yield
-10.79%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
77.73%
Operating margin
-11.75%
Net margin
-0.06%
Return on equity
-2.96%
Return on assets
-2.38%
Return on invested capital
-5.79%

Financial health

Debt / equity
0.01×
Current ratio
5.22×
Altman Z-score
13.99
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends322%-566%-1455%-2344%Gross margin, FY2021: 100.00%Gross margin, FY2023: -582.67%Gross margin, FY2024: -96.12%Gross margin, FY2025: 99.82%Operating margin, FY2021: -2121.65%Operating margin, FY2023: -902.50%Operating margin, FY2024: -159.26%Operating margin, FY2025: -16.76%Net margin, FY2021: -2076.35%Net margin, FY2023: -854.78%Net margin, FY2024: -140.87%Net margin, FY2025: -8.47%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2023 -582.67%. Gross margin FY2024 -96.12%. Gross margin FY2025 99.82%. Operating margin FY2021 -2121.65%. Operating margin FY2023 -902.50%. Operating margin FY2024 -159.26%. Operating margin FY2025 -16.76%. Net margin FY2021 -2076.35%. Net margin FY2023 -854.78%. Net margin FY2024 -140.87%. Net margin FY2025 -8.47%.

Income trends

Revenue

72.3M USD+153.52%

Operating income

−12.12M USD+73.32%

Net income

−6.12M USD+84.76%
Income trends across reported periods92.8M USD10.81M USD−71.19M USD−153.19M USDRevenue, FY2021: 6.25M USDRevenue, FY2023: 7.16M USDRevenue, FY2024: 28.52M USDRevenue, FY2025: 72.3M USDOperating income, FY2021: −132.69M USDOperating income, FY2022: −94.11M USDOperating income, FY2023: −64.65M USDOperating income, FY2024: −45.42M USDOperating income, FY2025: −12.12M USDNet income, FY2021: −129.86M USDNet income, FY2022: −93.09M USDNet income, FY2023: −61.23M USDNet income, FY2024: −40.18M USDNet income, FY2025: −6.12M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 6.25M USD. Revenue FY2023 7.16M USD. Revenue FY2024 28.52M USD. Revenue FY2025 72.3M USD. Operating income FY2021 −132.69M USD. Operating income FY2022 −94.11M USD. Operating income FY2023 −64.65M USD. Operating income FY2024 −45.42M USD. Operating income FY2025 −12.12M USD. Net income FY2021 −129.86M USD. Net income FY2022 −93.09M USD. Net income FY2023 −61.23M USD. Net income FY2024 −40.18M USD. Net income FY2025 −6.12M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue72.3M USD28.52M USD7.16M USD—6.25M USD
Cost of goods sold129K USD55.93M USD48.9M USD69.08M USD—
Gross profit72.17M USD−27.41M USD−41.74M USD−69.08M USD6.25M USD
Research and development64.81M USD55.93M USD48.9M USD69.98M USD68.52M USD
Selling, general, and administrative19.61M USD18.01M USD22.91M USD23.93M USD28.78M USD
Operating expenses84.42M USD18.01M USD22.91M USD25.03M USD138.94M USD
Interest income6M USD5.57M USD3.45M USD1.02M USD302K USD
Depreciation and amortization129K USD129K USD450K USD498K USD466K USD
Operating income−12.12M USD−45.42M USD−64.65M USD−94.11M USD−132.69M USD
Net income−6.12M USD−40.18M USD−61.23M USD−93.09M USD−129.86M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+64.76%
11 comparable reports
Latest EPS result
-0.2
Estimate -0.72 · Beat by 72.38%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.841.1-0.63-2.37Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual -1.57, estimate -1.75, surprise +10.29%, Beat. Q2 2025, reported May 8, 2025: actual -1.17, estimate -2.01, surprise +41.79%, Beat. Q3 2025, reported Aug 6, 2025: actual -1.33, estimate -0.653, surprise -103.57%, Miss. Q4 2025, reported Nov 10, 2025: actual -0.72, estimate -0.5, surprise -44.00%, Miss. Q1 2026, reported Mar 19, 2026: actual 2.48, estimate -0.51, surprise +586.27%, Beat. Q2 2026, reported May 7, 2026: actual -0.54, estimate -0.73, surprise +26.03%, Beat. Q3 2026, reported Aug 13, 2026: actual -0.2, estimate -0.724, surprise +72.38%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.624, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates45.58M31.39M17.2M3.02MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual 7.36M USD, estimate 3.55M USD, surprise +107.24%, Beat. Q2 2025, reported May 8, 2025: actual 9.42M USD, estimate 7.41M USD, surprise +27.03%, Beat. Q3 2025, reported Aug 6, 2025: actual 9.63M USD, estimate 9.32M USD, surprise +3.24%, Beat. Q4 2025, reported Nov 10, 2025: actual 10.79M USD, estimate 7.46M USD, surprise +44.64%, Beat. Q1 2026, reported Mar 19, 2026: actual 42.46M USD, estimate 7.42M USD, surprise +472.24%, Beat. Q2 2026, reported May 7, 2026: actual 8.21M USD, estimate 9.27M USD, surprise -11.36%, Miss. Q3 2026, reported Aug 13, 2026: actual 13.37M USD, estimate 8.6M USD, surprise +55.53%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate 7.93M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$47.50

38.16% upside
Past 12 months12-month forecastHigh $50.00Average $47.50Low $45.00

Rating distribution

11 ratings
Strong buy00%
Buy655%
Hold545%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions

ASMB news

zacks.com

Best Momentum Stocks to Buy for August 21st

LITE, ONTO and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 21st, 2026.

Read source
zacks.com

New Strong Buy Stocks for August 21st

MCY, ASMB, ONTO, BSET and UNH have been added to the Zacks Rank #1 (Strong Buy) List on August 21st, 2026.

Read source
zacks.com

Are You Looking for a Top Momentum Pick? Why Assembly Biosciences (ASMB) is a Great Choice

Does Assembly Biosciences (ASMB) have what it takes to be a top stock pick for momentum investors? Let's find out.

Read source
zacks.com

Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 40.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive…

Read source
seekingalpha.com

Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal

Assembly Biosciences is maintained at a 'Buy' rating, driven by pipeline advancement and a strong cash position. Key catalysts include phase 2 trials for GS-1179 in genital herpes and ABI-6250 in chronic HDV, PBC, and…

Read source
zacks.com

Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates

Assembly Biosciences (ASMB) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $1.33 per share a year ago.

Read source

ASMB peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ASMB

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
10.38M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
8.09M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
3.35M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.97M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.39M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
1.14M
Weight
0.08%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
723.04K
Weight
0.01%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
634.3K
Weight
0.00%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%

Continue in GoAI

Research ASMB

research.disclaimer